Asked and answered
How do I get Express Scripts to approve Mounjaro?
Your prescriber files a prior authorization that documents a type 2 diabetes diagnosis. That is the approval route Cigna, Express Scripts' parent company, publishes for Mounjaro, and an approval lasts one year. A request for weight loss alone does not meet that policy.
- Diagnosis first: Cigna's GLP-1 policy approves Mounjaro for 1 year with a documented type 2 diabetes diagnosis.
- Send it electronically: Express Scripts takes prior authorization through the prescriber's electronic health record, its ExpressPAth portal, CoverMyMeds or Surescripts. A prescriber who cannot use those can call 800.753.2851.
- Check the list: Mounjaro is on the Express Scripts National Preferred Formulary drug list for 2027.
- If it is denied: the same Express Scripts page explains how your prescriber asks for a coverage decision to be reconsidered.
- For weight loss, the same molecule is sold as Zepbound. Cigna's policy says the diabetes GLP-1s are not FDA-approved for weight loss without type 2 diabetes.
- Your employer's plan can differ: Cigna notes a customer's benefit plan document may differ significantly from its standard policy.
The 6 quotes behind this answer
- 1
“Mounjaro, Ozempic injection, Ozempic tablets, Rybelsus and Trulicity are considered medically necessary … Type 2 Diabetes Mellitus. Approve for 1 year if the patient meets the following (A): A) Diagnosis of Type 2 diabetes mellitus [Documentation Required]”
Cigna Coverage Policy IP 0701, effective 06/15/2026 · read 20 November 2026
- 2
“Call us at 800.753.2851, download a state specific fax form or fax your requests to the number shown on our general request form.”
Express Scripts prior authorization resources page · read 20 November 2026
- 3
“if you would like to make an appeal for us to reconsider a coverage decision”
Express Scripts prior authorization resources page · read 20 November 2026
- 4
“MOUNJARO … THIS DOCUMENT LIST IS EFFECTIVE JANUARY 1, 2027, THROUGH DECEMBER 31, 2027. THIS LIST IS SUBJECT TO CHANGE.”
Express Scripts National Preferred Formulary drug list, 2027 · read 20 November 2026
- 5
“The GLP-1 agonists and GLP-1/glucose-dependent insulinotropic polypeptide-1 agonist in this policy are not FDA-approved for weight loss in a patient who is overweight (body mass index [BMI] ≥ 27 kg/m2) or obese (BMI ≥ 30 kg/m2) without type 2 diabetes.”
Cigna Coverage Policy IP 0701, effective 06/15/2026 · read 20 November 2026
- 6
“the terms of a customer’s particular benefit plan document … may differ significantly from the standard benefit plans upon which these Coverage Policies are based.”
Cigna Coverage Policy IP 0701, effective 06/15/2026 · read 20 November 2026









